openPR Logo
Press release

Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B Infections

02-05-2018 03:31 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Hepatitis B Therapeutics Market Is Driven by Rising Incidence

Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and stops development of liver cancer and chronic disease caused by hepatitis B. It can cause a long term infection and put people at high risk of liver cancer and cirrhosis that may lead to death. Globally, hepatitis B is one of the major health problems that spreads by mucosal or percutaneous exposure as well as through menstrual, seminal, saliva, and vaginal fluids. Hepatitis B can occur due to sexual transmission, by having contact with sex workers and sex with multiple partners. Transmission of disease may also occur due to reuse of syringes and needles both among persons who inject drugs and in health care settings. Moreover, it may occur during surgical, medical, and dental procedures, and use of razors that are contaminated with infected blood. Infants and young children mostly get chronic hepatitis B.

Get Brochure of Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=144

Limited access to treatment and diagnosis of hepatitis B in many resource constrained settings and increasing prevalence of hepatitis B infections are likely to drive the global hepatitis B therapeutics market during the forecast period. Rising awareness and increasing affordability are some of the key factors that will increase the rate of diagnosis before a person having advanced liver disease. According to the World Health Organization (WHO), infection of chronic hepatitis B is most common in infants. Rising incidence of hepatitis B infections is a major driver of the market. Less availability of antibiotics in the market and effectiveness of antivirals against hepatitis B infections is likely to propel the market during the forecast period. Prevalence of hepatitis B is increasing steadily across the globe. Medications and treatment options are highly expensive. These are the major drivers of the hepatitis B therapeutics market.

Get Discount on Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=144

That said, the market for HIV therapeutics potentially remains in billions, with new patent trials being conducted every year. HIV market therefore remains highly attractive in terms of novel drugs and their impact globally. Asian manufacturers are proving to be a tough competition with their unique patent laws that circumvent patent of essential life saving medicines. The prices too are bound to decrease with the entry of such manufacturers, thereby potentially increasing therapeutics market in terms of volume. The North American HIV market is the highest market globally, by value and occupies more than 50% of the global revenue generated from HIV antiviral; this is followed by the European market at around 30% of the global market. The growth in these regions is mainly attributed to high affordability of drugs along with a range of health insurance coverage. In developing markets of Asia and South America, the leading cause of death is their poor healthcare standards. This along with their population size make for a potentially large market, however unavailability of affordable drugs is often the reason why markets haven’t been proliferated as of yet. On the other hand, the recent growth of market in Asia Pacific is a positive sign for potential manufacturers. The rest of the world also follows a similar pattern like Asia. Overall the Asian, African and South American region contribute less than 20% share in the global HIV market. 

Report Details at https://www.transparencymarketresearch.com/hepatitis-b-market.html

Major players operating in the global hepatitis B therapeutics market are GlaxoSmithKline plc, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax SA, F. Hoffmann- La Roche, Novartis AG, and Merck & Co. The increasing competition among key players is likely to drive the global hepatitis B therapeutics market during the forecast period. 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B Infections here

News-ID: 931734 • Views:

More Releases from Transparency Market Research

Non-Destructive Testing Market Projected to Reach $31.9 Billion by 2034: TMR Analysis
Non-Destructive Testing Market Projected to Reach $31.9 Billion by 2034: TMR Ana …
The Global Non-Destructive Testing (NDT) Market (비파괴 검사(NDT) 시장) is set to witness significant growth, projected to reach an estimated value of $31.9 billion by the end of 2034. This growth trajectory follows a valuation of $15.5 billion in 2023, fueled by a compound annual growth rate (CAGR) of 6.7% from 2024 to 2034. The increase in demand for inspection and health monitoring of concrete and steel structures is a primary
Outdoor Power Equipment Market Set to Reach $42.8 Billion by 2034, Driven by Sustainable Solutions and Growing Landscaping Demand
Outdoor Power Equipment Market Set to Reach $42.8 Billion by 2034, Driven by Sus …
The Global Outdoor Power Equipment Market (屋外用電動機器市場), valued at $30.5 billion in 2023, is projected to experience robust growth over the next decade. According to recent industry analysis, the market is expected to grow at a compound annual growth rate (CAGR) of 3.1%, reaching an estimated $42.8 billion by 2034. This growth is largely attributed to the increasing adoption of landscaping services and a rising demand for sustainable solutions in
Global Semiconductor IP Market to Reach $13.5 Billion by 2034, Growing at a 5.9% CAGR: TMR Analysis
Global Semiconductor IP Market to Reach $13.5 Billion by 2034, Growing at a 5.9% …
The Global Semiconductor Intellectual Property (IP) Market (반도체 지적재산권(IP) 시장), valued at US$ 7.1 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2034, reaching US$ 13.5 billion by the end of the forecast period. This growth is primarily fueled by increasing demand for AI-based applications across various industries and government initiatives aimed at modernizing defense technologies. Download Sample PDF from
Glass Wafer Carrier Market to Surge, Expected to Reach $2.2 Billion by 2031: TMR Analysis
Glass Wafer Carrier Market to Surge, Expected to Reach $2.2 Billion by 2031: TMR …
The Global Glass Wafer Carrier Market (ガラスウェーハキャリア市場) is poised for significant growth, expected to reach a valuation of US$ 2.2 billion by 2031, advancing at a remarkable CAGR of 19.2% from 2024. The surge in demand for semiconductors in automotive and IT & telecommunications sectors is driving this trend, positioning glass wafer carriers as critical components in semiconductor manufacturing processes. Analysts indicate that the automotive industry's increased focus on vehicle safety,

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Hepatitis C Drug Market: Global Hepatitis C Drug Share Will Reach $27.63 billion …
Zion Market Research has published a new report titled “Hepatitis C Drug Market for (Hospitals, Private Labs, Physician Offices, Public Health Labs and Blood Banks) by Application – Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” According to the report, global demand for hepatitis C drug market was valued at USD 11.81 billion in 2015, is expected to reach USD 27.63 billion in 2021 and is anticipated to